PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has reported promising early results in the clinical trial of their drug candidate for Retinitis Pigmentosa type 11 (RP11), a childhood blinding eye disease. The drug has been deemed safe and well tolerated over three different dosing levels, paving the way for further studies and higher dosing in a Multiple Ascending Dose study set to begin in Q2 2024. Successful outcomes from these trials could lead to a registrational trial in 2025, aiming to meet a significant unmet need for RP11 patients.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
